| Kovatchev, Boris |
| Completed | N/A | 15 | US | Neural-net Artificial Pancreas, NAP, University of Virginia Model Predictive Control, UMPC | University of Virginia, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Type1 Diabetes | 09/23 | 09/23 | | |
| Recruiting | N/A | 20 | US | Control-IQ use in Type 2 Diabetes under basal insulin injections, Tandem Diabetes Care | University of Virginia, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Type 2 Diabetes | 01/25 | 01/25 | | |
| Recruiting | N/A | 16 | US | Automated Insulin Delivery Adaptive NETwork (AIDANET), AIDANET→AIDANET+ BPS_RL, AIDANET+ BPS_RL→AIDANET, Group B | Sue Brown, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), DexCom, Inc. | Type 1 Diabetes | 12/25 | 12/25 | | |
| Active, not recruiting | N/A | 42 | US | Artificial Pancreas (AP) | University of Virginia, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), DexCom, Inc., Tandem Diabetes Care, Inc. | Type 1 Diabetes | 10/25 | 10/25 | | |
| Badano, Luigi P |
| Recruiting | N/A | 1500 | Europe | Echocardiography | Istituto Auxologico Italiano, Denisa Muraru, Michele Tomaselli, Mara Gavazzoni | Heart Valve Incompetence, Echocardiography, Transthoracic | 04/25 | 04/27 | | |
| Recruiting | N/A | 1050 | Europe | Personalized risk model | Istituto Auxologico Italiano | Sudden Cardiac Death Due to Cardiac Arrhythmia, Cardiomyopathies, Ischemic Heart Disease, Cardiovascular Diseases | 12/24 | 04/25 | | |
| Recruiting | N/A | 3500 | Europe | COMPACS | Istituto Auxologico Italiano, Medimatic S.R.L., Genova, Italy | Echocardiography | 09/25 | 09/26 | | |
NCT05749107: In-depth Characterization of Atriogenic Secondary Tricuspid Regurgitation Due to Atrial Fibrillation |
|
|
| Recruiting | N/A | 1050 | Europe | Echocardiography, Proteomic analyses | Istituto Auxologico Italiano, Ministry of Health, Italy | Heart Valve Incompetence, Atrial Fibrillation, Persistent | 12/24 | 11/25 | | |
| Recruiting | N/A | 500 | Europe | | Humanitas Hospital, Italy, Centro Cardiologico Monzino, IRCCS Policlinico S. Donato, Istituti Clinici Scientifici Maugeri SpA, Istituto Auxologico Italiano | Covid19, Myocardial Injury, Cardiovascular Diseases, Heart Failure, Cardiovascular Morbidity | 06/21 | 10/21 | | |
| Trevisanuto, Daniele |
NEOSUC, NCT05472155: SUCTIONING AT BIRTH WITH BULB SYRINGE OR SUCTION CATHETER: A RANDOMIZED CONTROLLED TRIAL |
|
|
| Completed | N/A | 60 | RoW | Bulb syringe, Suction catheter | University Hospital Padova, Doctors with Africa - CUAMM | Neonatal Resuscitation | 10/22 | 10/22 | | |
NEU-VODEtec, NCT06758492: A Prospective Observational Study of Video Laryngoscopy Versus Direct Laryngoscopy for Insertion of a Thin Endotracheal Catheter for Surfactant Administration in Newborn Infants |
|
|
| Not yet recruiting | N/A | 600 | Europe, RoW | Video laryngoscopy used to insert thin endotracheal catheter, Direct laryngoscopy used to insert thin endotracheal catheter | University College Dublin, Leiden University Medical Center | Respiratory Distress Syndrome (Neonatal), Respiratory Distress Syndrome (RDS), Video Laryngoscopy, Surfactant | 12/25 | 12/25 | | |
NEU-VODE, NCT06757543: A Stepped Wedge Cluster Randomised Trial of Video Versus Direct Laryngoscopy for Intubation of Newborn Infants |
|
|
| Not yet recruiting | N/A | 840 | Europe, RoW | Video laryngoscopy, Direct laryngoscopy with standard laryngoscope | University College Dublin, National Maternity Hospital, Ireland, Leiden University Medical Center | Intubation, Intubation Complications, Infant, Newborn, Infant Respiratory Distress Syndrome, Video Laryngoscopy | 12/25 | 12/25 | | |
| Antonini, Angelo |
| Completed | 3 | 507 | Europe, US, RoW | Tavapadon, PF-06649751, CVL-751, Placebo | Cerevel Therapeutics, LLC | Parkinson Disease | 01/24 | 02/24 | | |
| Completed | 3 | 522 | Europe, Canada, US, RoW | Tavapadon, PF-06649751, CVL-751, Placebo | Cerevel Therapeutics, LLC | Parkinson Disease | 06/24 | 06/24 | | |
| Active, not recruiting | 2/3 | 110 | Europe, US | AMX0035, Placebo | Amylyx Pharmaceuticals Inc. | Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases, Atypical Parkinsonism | 04/26 | 11/29 | | |
| Active, not recruiting | 2 | 159 | Europe, Japan, US | TAK-341, MEDI1341, Placebo | Takeda, AstraZeneca | Multiple System Atrophy | 07/25 | 07/25 | | |
ACTIVATE, NCT05819359: Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD |
|
|
| Active, not recruiting | 2 | 237 | Europe, Canada, US | BIA 28-6156 10 mg, BIA 28-6156 60 mg, Placebo | Bial R&D Investments, S.A. | Parkinson's Disease | 03/26 | 07/26 | | |
PD_Pal, NCT05954013: Advance Care Planning and Care Coordination for People With Parkinson's Disease |
|
|
| Completed | N/A | 189 | Europe | PD_Pal intervention | Radboud University Medical Center, University of Padova, University of Ioannina, University College, London, Estonian Movement Disorders Society, Paracelsus Medical University, Philipps University Marburg Medical Center, Skane University Hospital, Mediolanum Cardio Research | Parkinson Disease, Parkinsonism | 03/23 | 03/23 | | |
| Sergi, Giuseppe |
APPROACH, NCT05719870: A Multidisciplinary Approach to Improve Adherence to Medical Recommendations in Older Adults |
|
|
| Recruiting | N/A | 360 | Europe | Educational training | University Hospital of Ferrara, University of Padova | Medication Adherence, Aging, Multidisciplinary Communication, Fall, Hospital Discharge | 02/23 | 02/23 | | |
| Bruttomesso, Daniela |
NCT06147583: Assessing Detection Algorithms for Insulin Pump Malfunctions in Type 1 Diabetes |
|
|
| Not yet recruiting | N/A | 20 | Europe | Simulation of an insulin pump failure | University of Padova, Azienda Ospedaliera di Padova | Diabetes Mellitus, Type I | 02/24 | 04/24 | | |
| Pratesi, Simone |
NCT06270368: Children Born Preterm: Sustainable Health Monitoring |
|
|
| Recruiting | N/A | 650 | Europe | | Meyer Children's Hospital IRCCS, IRCCS Fondazione Stella Maris | Premature Birth | 08/25 | 12/25 | | |
| Completed | N/A | 212 | Europe | placental circulation intact, cord milking | University of Florence | Placental Transfusion | 07/23 | 09/23 | | |
| Recruiting | N/A | 906 | Europe, US, RoW | Positive End-Expiratory Pressure (PEEP) | Murdoch Childrens Research Institute, University of Pennsylvania, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), University of Oxford | Lung Injury, Preterm Birth | 11/26 | 05/28 | | |
| Lista, Gianluca |
| Recruiting | N/A | 607 | Europe, Canada | NIRS group | Medical University of Graz, Medical University Innsbruck, Medical University of Vienna, Vittore Buzzi Children's Hospital, University Hospital Tuebingen, University College Cork, University Hospital Freiburg, Poznan University of Medical Sciences, University Medical Centre Ljubljana, IRCCS Burlo Garofolo, University of Alberta | Neurodevelopmental Disability, Death | 10/24 | 12/24 | | |
| Recruiting | N/A | 668 | Europe | Lung ultrasound score (LUS) | Azienda Ospedaliero-Universitaria Careggi | Respiratory Distress Syndrome, Newborn | 01/24 | 07/24 | | |
NCT05823909: A Randomized, Multicenter Study of the Safety and Performance of Fabian PRICO for Saturation Targeting With Non-invasive Respiratory Support |
|
|
| Not yet recruiting | N/A | 47 | Europe | fabian Therapy evolution ventilators with PRICO (Predictive Intelligent Control of Oxygenation), fabian Therapy evolution ventilators with manual FiO2 control | Vyaire Medical | Respiratory Insufficiency Syndrome of Newborn | 06/24 | 08/24 | | |
NCT05853991: Effects of Touch on Brain Connectivity and Metabolic Biomarkers in Preterm Infants |
|
|
| Not yet recruiting | N/A | 20 | Europe | osteopathic manipulative treatment, Active comparator, Placebo | Come Collaboration | Preterm, Infant ALL, Premature, Disease | 03/25 | 03/26 | | |
| Recruiting | N/A | 906 | Europe, US, RoW | Positive End-Expiratory Pressure (PEEP) | Murdoch Childrens Research Institute, University of Pennsylvania, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), University of Oxford | Lung Injury, Preterm Birth | 11/26 | 05/28 | | |
| Coordinator, Site |
NCT05069597: Study to Evaluate Symptoms of Exocrine Pancreatic Insufficiency in Adult Participants With Cystic Fibrosis or Chronic Pancreatitis Treated With Creon |
|
|
| Completed | 4 | 30 | US | CREON, Pancrelipase | AbbVie | Cystic Fibrosis, Chronic Pancreatitis | 07/23 | 08/23 | | |
NCT05647551: A Study to Evaluate Satisfaction in Adult Participants With the Aesthetics of the Periorbital Area After JUVÉDERM® Fillers and BOTOX®/VISTABEL® Injections |
|
|
| Completed | 4 | 73 | Europe, RoW | BOTOX®/VISTABEL®, Juvéderm® VOLBELLA® with Lidocaine, Juvéderm® VOLIFT® with Lidocaine, Juvéderm® VOLUMA® with Lidocaine | AbbVie | Facial Corrections, Facial Lines | 10/23 | 10/23 | | |
NCT01192568: Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder |
|
|
| Completed | 4 | 52 | US | Oxybutynin, Gelnique, Placebo | AbbVie | Overactive Detrusor, Neurogenic Bladder | 08/23 | 10/23 | | |
NCT06218251: A Study to Evaluate Participant Satisfaction and Natural Outcomes Following Administration of BOTOX Cosmetic Injections in Adult Participants for Treatment of Upper Facial Lines |
|
|
| Completed | 4 | 100 | Canada, US | BOTOX, Botulinum Toxin Type A, OnabotulinumtoxinA | AbbVie | Upper Facial Lines | 07/24 | 12/24 | | |
IMMpactful, NCT06333860: A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) |
|
|
| Active, not recruiting | 4 | 393 | Europe, Canada, US, RoW | Risankizumab, Deucravacitinib | AbbVie | Moderate Plaque Psoriasis | 03/25 | 03/26 | | |
NCT05969223: Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis |
|
|
| Active, not recruiting | 4 | 214 | US | Risankizumab, Skyrizi, ABBV-066, Placebo for Risankizumab | AbbVie | Genital Psoriasis, Scalp Psoriasis | 01/25 | 10/25 | | |
| Completed | 4 | 461 | Europe, Canada, Japan, RoW | Upadacitinib, RINVOQ, ABT-494 | AbbVie, AbbVie Inc. | Atopic Dermatitis | 07/24 | 08/24 | | |
VIALE-M, NCT04102020 / 2019-002217-19: A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy |
|
|
| Active, not recruiting | 3 | 112 | Europe, Canada, Japan, US, RoW | Venetoclax, ABT-199, GDC-0199, Venclexta, Azacitidine | AbbVie, Roche-Genentech | Acute Myeloid Leukemia (AML) | 09/22 | 04/25 | | |
NCT04994535 / 2021-000240-22: A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence |
|
|
| Completed | 3 | 426 | Europe, Canada, US | OnabotulinumtoxinA, BOTOX, Placebo | AbbVie, AbbVie Inc. | Platysma Prominence | 06/23 | 06/23 | | |
NCT05139121: Study of the Safety and Efficacy of MR-100A-01 in Approximately 1200 Healthy Women for up to 13 Cycles |
|
|
| Completed | 3 | 1319 | Canada, US | MR-100A-01, Transdermal contraceptive delivery system | Mylan Technologies Inc., Mylan Inc. | Contraception | 01/25 | 01/25 | | |
NCT02814916 / 2014-005281-30: Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA |
|
|
| Completed | 3 | 199 | Europe, US, RoW | Dalbavancin, Xydalba, Vancomycin, Oxacillin, Flucloxacillin, Cefadroxil, Clindamycin | AbbVie | Methicillin-Resistant Staphylococcus Aureus, Bacterial Infections, Staphylococcal Skin Infections | 01/24 | 01/24 | | |
NCT06174688: A Study to Assess the Adverse Events and Effectiveness of BOTOX Injections for the Treatment of Moderate to Severe Forehead Lines in Chinese Adult Participants |
|
|
| Completed | 3 | 140 | RoW | BOTOX, Botulinum Toxin Type A, Placebo | AbbVie | Forehead Lines | 09/24 | 09/24 | | |
EPCORE FL-2, NCT06191744: Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma |
|
|
| Recruiting | 3 | 1080 | Europe, Japan, US, RoW | Epcoritamab, ABBV-GMAB-3013, GEN3013, Epkinly, Prednisone, Rituximab, Lenalidomide, Doxorubicin, Vincristine, Cyclophosphamide, Obinutuzumab, Bendamustine | Genmab, AbbVie | Follicular Lymphoma (FL) | 11/37 | 11/37 | | |
| Active, not recruiting | 3 | 429 | Europe, Canada, Japan, US, RoW | Upadacitinib, ABT-494, RINVOQ, Corticosteroid (CS), Placebo | AbbVie | Giant Cell Arteritis (GCA) | 02/24 | 03/25 | | |
|
|
|
|
NCT04903626 / 2020-005777-27: Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB) |
|
|
| Completed | 3 | 286 | Europe, Canada, US, RoW | Glecaprevir/Pibrentasvir (GLE/PIB), ABT-493/ABT-530, Mavyret | AbbVie | Hepatitis C Virus (HCV) | 09/24 | 09/24 | | |
Level Up, NCT05601882 / 2022-002482-15: A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis |
|
|
| Completed | 3 | 926 | Europe, Canada, Japan, US, RoW | Upadacitinib, RINVOQ, Dupilumab | AbbVie, AbbVie Inc. | Atopic Dermatitis | 03/24 | 08/24 | | |
NCT06387394: A Study to Assess BOTOX Injections in Adult Participants for the Change of Masseter Muscle Prominence |
|
|
| Active, not recruiting | 3 | 202 | US | BOTOX, OnabotulinumtoxinA, Placebo | AbbVie | Masseter Muscle Prominence | 12/25 | 12/25 | | |
NCT06158841: Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma |
|
|
| Recruiting | 3 | 380 | Europe, Japan, US, RoW | Etentamig, ABBV-383, Carfilzomib, Pomalidomide, Elotuzumab, Selinexor, Bortezomib, Dexamethasone | AbbVie | Multiple Myeloma | 12/27 | 12/27 | | |
Switch-Up, NCT06389136: A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab |
|
|
| Recruiting | 3 | 300 | Japan, US, RoW | Upadacitinib Dose A, ABT-494, RINVOQ, Dupilumab Dose A, Upadacitinib Dose B | AbbVie | Atopic Dermatitis | 08/25 | 03/26 | | |
NCT06468228: A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa |
|
|
| Recruiting | 3 | 1280 | Europe, Canada, Japan, US, RoW | Lutikizumab, ABT-981, Placebo | AbbVie | Hidradenitis Suppurativa | 12/26 | 12/26 | | |
| Completed | 3 | 775 | Europe, Canada, US, RoW | BOTOX, Botulinum Toxin Type A, Placebo | AbbVie | Episodic Migraine | 11/24 | 11/24 | | |
|
NCT06428019: A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) |
|
|
| Recruiting | 3 | 120 | Europe, US, RoW | Venetoclax, ABT-199, Acalabrutinib, Obinutuzumab | AbbVie | Chronic Lymphocytic Leukemia | 10/26 | 10/26 | | |
EPCORE DLBCL-4, NCT06508658: A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma |
|
|
| Recruiting | 3 | 320 | Europe, Japan, US, RoW | Epcoritamab, ABBV-GMAB-3013, Epkinly, Rituximab, Lenalidomide, Oxaliplatin, Gemcitabine | Genmab | Diffuse Large B-Cell Lymphoma | 01/28 | 01/28 | | |
TRANSFORM-2, NCT04468984 / 2020-000557-27: Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis |
|
|
| Active, not recruiting | 3 | 295 | Europe, Canada, Japan, US, RoW | Navitoclax, ABT-263, Ruxolitinib, Best Available Therapy (BAT) | AbbVie | Myelofibrosis (MF) | 02/25 | 12/26 | | |
|
|
Start Up, NCT06461897: A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis |
|
|
| Recruiting | 3 | 675 | Europe, Canada, US, RoW | Upadacitinib, ABT-494, RINVOQ®, RINVOQ LQ, Dupilumab | AbbVie | Atopic Dermatitis | 07/30 | 07/30 | | |
UBRO MM, NCT06417775: Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine |
|
|
| Recruiting | 3 | 450 | US | Ubrogepant, UBRELVY, Placebo for Ubrogepant | AbbVie | Migraine | 09/27 | 09/27 | | |
NCT05316220: A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years With Ulcerative Colitis |
|
|
| Not yet recruiting | 3 | 80 | US | Mesalamine, Delzicol, Placebo | AbbVie | Ulcerative Colitis (UC) | 07/26 | 07/26 | | |
LINZESS, NCT04026113 / 2019-001500-38: Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC) |
|
|
| Completed | 3 | 438 | Europe, Canada, US, RoW | Linaclotide, Placebo | AbbVie, Ironwood Pharmaceuticals, Inc. | Functional Constipation, Irritable Bowel Syndrome With Constipation | 05/24 | 05/24 | | |
| Completed | 3 | 150 | Europe, Canada, Japan, US | Risankizumab, SKYRIZI, ABBV-066, Ustekinumab | AbbVie | Psoriasis | 02/24 | 10/24 | | |
NCT05439616: Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD |
|
|
| Completed | 3 | 161 | US | Cariprazine, VRAYLAR, AGN-241780, Placebo | AbbVie | Autism Spectrum Disorder | 10/24 | 10/24 | | |
NCT05652205: A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation |
|
|
| Active, not recruiting | 3 | 123 | Europe, US | Linaclotide, Placebo for Linaclotide | AbbVie, Ironwood Pharmaceuticals, Inc. | Functional Constipation (FC), Chronic Idiopathic Constipation (CIC) | 08/25 | 11/25 | | |
NCT06629597: A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma |
|
|
| Not yet recruiting | 3 | 400 | RoW | YL201, Docetaxel, Capecitabine, Gemcitabine | MediLink Therapeutics (Suzhou) Co., Ltd. | Nasopharyngeal Carcinoma | 12/27 | 12/28 | | |
NCT06612151: A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer |
|
|
| Not yet recruiting | 3 | 438 | RoW | YL201, topotecan hydrochloride for injection | MediLink Therapeutics (Suzhou) Co., Ltd. | Small Cell Lung Cancer | 12/27 | 12/30 | | |
ELARIS EM-COC, NCT04333576: Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain |
|
|
| Recruiting | 3 | 800 | US | Elagolix, ABT-620, Orilissa, Placebo, Combined Oral Contraceptive | AbbVie | Endometriosis | 03/29 | 06/30 | | |
NCT05216263: Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine |
|
|
| Active, not recruiting | 3 | 75 | US | Atogepant, QULIPTA | AbbVie | Chronic Migraine | 04/25 | 04/25 | | |
NCT05316233: A Study to Assess Adverse Events and Change in Disease Activity of JUVÉDERM® VOLITE™ XC Injectable Gel for Change in Neck Appearance in Adult Participants |
|
|
| Completed | 3 | 159 | US | VOLITE XC, JUVÉDERM® VOLITE™ XC | AbbVie | Neck Lines | 09/24 | 09/24 | | |
NCT05452070: A Study to Assess Adverse Events and Change in Disease Activity of HArmonyCa Lidocaine Injectable Gel for Mid Face Soft Tissue Augmentation in Adult Participants |
|
|
| Active, not recruiting | 3 | 171 | Europe, Canada | HArmonyCa Lidocaine Injectable Gel | Allergan | Mid Face Volume Deficit | 05/25 | 05/25 | | |
Up-AA, NCT06012240: A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata |
|
|
| Active, not recruiting | 3 | 1399 | Europe, Canada, Japan, US, RoW | Upadacitinib, Rinvoq, ABT-494, Placebo | AbbVie | Alopecia Areata | 01/28 | 01/28 | | |
TeliMET NSCLC-01, NCT04928846 / 2021-001811-94: A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 3 | 698 | Europe, Canada, Japan, US, RoW | Telisotuzumab Vedotin, ABBV-399, Docetaxel | AbbVie | Non Small Cell Lung Cancer | 03/28 | 03/28 | | |
NCT05995340: ELAPR002f Injectable Gel in the Treatment of Atrophic Acne Scars |
|
|
| Recruiting | 3 | 156 | Europe, Canada | ELAPR002f Injectable Gel, Saline Active Control | AbbVie | Atrophic Acne Scars | 02/26 | 02/26 | | |
NCT04578756: Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder |
|
|
| Active, not recruiting | 3 | 310 | US | Cariprazine Flexible Dose | AbbVie | Schizophrenia, Bipolar I Disorder, Autism Spectrum Disorder (ASD) | 09/25 | 09/25 | | |
| Completed | 3 | 1 | US | StrataGraft | Stratatech, a Mallinckrodt Company, Biomedical Advanced Research and Development Authority | Skin Wound, Burns, Trauma-related Wound | 05/24 | 05/24 | | |
NCT03850782 / 2018-002574-52: Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension |
|
|
| Active, not recruiting | 3 | 515 | Europe, US, RoW | Bimatoprost (SR) | AbbVie | Open-Angle Glaucoma, Ocular Hypertension | 08/25 | 08/25 | | |
NCT05411198: Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle Glaucoma |
|
|
| Recruiting | 3 | 65 | US, RoW | XEN45 (Glaucoma Gel Stent) | AbbVie | Open-Angle Glaucoma | 08/25 | 08/25 | | |
SELECT- SWITCH, NCT05814627: Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis |
|
|
| Recruiting | 3 | 480 | Europe, Canada, Japan, US, RoW | Upadacitinib, RINVOQ, Adalimumab, Humira, Upadacitinib Matching Placebo, Adalimumab Matching Placebo | AbbVie | Rheumatoid Arthritis | 09/25 | 08/26 | | |
| Active, not recruiting | 3 | 490 | Europe, Japan, RoW | Trastuzumab deruxtecan, T-DXd, DS-8201a, ENHERTU®, Ramucirumab, CYRAMZA®, Paclitaxel | Daiichi Sankyo, AstraZeneca | Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | 10/25 | 02/26 | | |
|
|
|
|
Step-Up HS, NCT05889182: A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy |
|
|
| Recruiting | 3 | 1328 | Europe, Canada, Japan, US, RoW | Upadacitinib, ABT-494, RINVOQ, Placebo | AbbVie | Hidradenitis Suppurativa | 10/25 | 08/27 | | |
CANOVA, NCT03539744 / 2017-003838-88: A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma. |
|
|
| Active, not recruiting | 3 | 265 | Europe, Canada, Japan, US, RoW | Pomalidomide, Pomalyst, Dexamethasone, Venetoclax, ABT-199, GDC-0199 | AbbVie, Roche-Genentech | Multiple Myeloma | 08/26 | 08/26 | | |
|
NCT06063967: A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease. |
|
|
| Recruiting | 3 | 276 | Europe, Canada, Japan, US, RoW | Risankizumab SC, ABBV-066, SKYRIZI, Placebo for risankizumab | AbbVie | Crohn's Disease | 07/27 | 02/29 | | |
NCT05125302: Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) |
|
|
| Recruiting | 3 | 1059 | US | Ubrogepant, Ubrelvy, Placebo-Matching Ubrogepant | AbbVie | Migraine | 05/26 | 05/26 | | |
TEMPLE, NCT05748483: Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With Migraine |
|
|
| Active, not recruiting | 3 | 545 | Europe, Canada, RoW | Atogepant, QULIPTA, Placebo for Atogepant, Topiramate, Placebo for Topiramate | AbbVie | Migraine | 04/25 | 05/26 | | |
NCT04064827: A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD) |
|
|
| Recruiting | 3 | 16 | US | Paricalcitol | AbbVie | Chronic Kidney Disease (CKD), Secondary Hyperparathyroidism (SHPT) | 06/26 | 10/26 | | |
NCT06100744: A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab |
|
|
| Recruiting | 3 | 40 | Europe, Canada, US, RoW | Adalimumab, Risankizumab, ABBV-066, Skyrizi | AbbVie | Juvenile Psoriatic Arthritis | 09/26 | 10/28 | | |
SELECT-SLE, NCT05843643: Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, Japan, US, RoW | Upadacitinib, RINVOQ, Placebo | AbbVie | Systemic Lupus Erythematosus | 10/26 | 10/27 | | |
VIALE-T, NCT04161885 / 2019-002621-30: A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML) |
|
|
| Active, not recruiting | 3 | 465 | Europe, Canada, Japan, US, RoW | Venetoclax, ABT-199, GDC-0199, VENCLEXTA, Azacitidine, Best Supportive Care (BSC) | AbbVie | Acute Myeloid Leukemia (AML), Cancer | 04/25 | 11/26 | | |
EPCORE DLBCL-2, NCT05578976 / 2021-000168-31: A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) |
|
|
| Recruiting | 3 | 900 | Europe, Canada, Japan, US, RoW | Epcoritamab, ABBV-GMAB-3013, Cyclophosphamide, Rituximab, Vincristine, Doxorubicin, Prednisone | Genmab, AbbVie | Diffuse Large B-Cell Lymphoma | 06/27 | 12/29 | | |
NCT05609630: Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis. |
|
|
| Recruiting | 3 | 90 | Europe, Japan, US, RoW | Upadacitinib, RINVOQ, ABT-494, Tocilizumab | AbbVie | Juvenile Idiopathic Arthritis | 06/29 | 06/29 | | |
DESTINY-Breast15, NCT05950945: Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer |
|
|
| Recruiting | 3 | 250 | Europe, US, RoW | Trastuzumab Deruxtecan, T-DXd, DS-8201a (trastuzumab derextecan), Enhertu® | Daiichi Sankyo, AstraZeneca | Breast Cancer | 10/27 | 10/27 | | |
NCT05711394: A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine |
|
|
| Recruiting | 3 | 450 | Europe, Canada, Japan, US, RoW | Atogepant, QULIPTA, AGN-241689, Placebo-Matching Atogepant | AbbVie | Episodic Migraine | 03/28 | 05/28 | | |
U-ASTOUND, NCT05782907: Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis. |
|
|
| Recruiting | 3 | 110 | Europe, Canada, Japan, US, RoW | Upadacitinib, RINVOQ | AbbVie | Ulcerative Colitis | 08/28 | 10/33 | | |
RISE, NCT05995353: A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease |
|
|
| Recruiting | 3 | 110 | Europe, Canada, US, RoW | Risankizumab, ABBV-066, SKYRIZI | AbbVie | Crohn's Disease | 04/29 | 04/29 | | |
NCT05707949: Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Migraine |
|
|
| Enrolling by invitation | 3 | 650 | Europe, Canada, Japan, US, RoW | Atogepant, QULIPTA, AGN-241689 | AbbVie | Migraine Prophylaxis | 11/29 | 11/29 | | |
EPCORE FL-1, NCT05409066 / 2021-000169-34: Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma |
|
|
| Active, not recruiting | 3 | 549 | Europe, Canada, Japan, US, RoW | Epcoritamab, GEN3013, Rituximab, Lenalidomide | Genmab, AbbVie | Follicular Lymphoma (FL) | 10/30 | 10/30 | | |
LIVIGNO-4, NCT06236438: Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 2/3 | 840 | Japan, US, RoW | Livmoniplimab, ABBV-151, Budigalimab, ABBV-181, Pembrolizumab, Pemetrexed, Cisplatin, Carboplatin | AbbVie | Non-Small Cell Lung Cancer | 10/31 | 10/31 | | |
NCT06345339: A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants |
|
|
| Recruiting | 2/3 | 2800 | US | Armour Thyroid, AGN-282176, Levothyroxine, Synthetic T4 | AbbVie | Hypothyroidism | 06/28 | 06/28 | | |
LIVIGNO-2, NCT06109272: A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) |
|
|
| Recruiting | 2/3 | 660 | Europe, US, RoW | Livmoniplimab, ABBV-151, Budigalimab, ABBV-181, Durvalumab, Atezolizumab, Bevacizumab, Tremelimumab | AbbVie | Hepatocellular Carcinoma | 09/30 | 09/30 | | |
NCT04853368 / 2020-005805-25: Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Adult Participants With Cystic Fibrosis |
|
|
| Terminated | 2 | 48 | Europe, US, RoW | ABBV-576, Galicaftor, ABBV-2222, Placebo, Navocaftor, ABBV-3067, ABBV-119 | AbbVie | Cystic Fibrosis (CF) | 06/23 | 06/23 | | |
|
AIM-CD, NCT05068284 / 2021-002869-18: A Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Intravenous (IV) Infusion and Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Crohn's Disease |
|
|
| Terminated | 2 | 176 | Europe, Canada, Japan, US, RoW | ABBV-154, Placebo | AbbVie, AbbVie Inc., Abbvie Inc. | Crohn's Disease | 07/23 | 07/23 | | |
|
NCT03339128 / 2017-003770-14: Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children |
|
|
| Recruiting | 2 | 95 | Europe, Canada, US | Eluxadoline, Viberzi, Placebo | AbbVie | Irritable Bowel Syndrome | 12/26 | 12/26 | | |
NCT06151535: A Study to Evaluate the Safety and Effectiveness of ELAPR002f Injectable Gel for the Improvement of Skin Quality in Adult Participants |
|
|
| Active, not recruiting | 2 | 30 | Europe | ELAPR002f Injectable Gel | AbbVie | Skin Quality Deficit | 01/25 | 01/25 | | |
| Completed | 2 | 13 | US | AG Tx, Meshed Autograft, SOMA Tx, StrataGraft skin tissue Overlay of Meshed Autograft (SOMA) | Stratatech, a Mallinckrodt Company | Full Thickness Thermal Burn | 03/24 | 03/24 | | |
NCT06241846: A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC |
|
|
| Recruiting | 2 | 100 | RoW | YL201 for Injection | MediLink Therapeutics (Suzhou) Co., Ltd. | Metastatic Castration-resistant Prostate Cancer (mCRPC) | 02/27 | 02/29 | | |
